Antibody Engineering Scientific Advisory Board

Richard H.J. Begent, M.D., Emeritus Professor of Oncology, UCL Cancer Institute, University College London, United Kingdom

Andrew Bradbury, Ph.D., M.B., B.S., Research Scientist and Team Leader, Los Alamos National Laboratories

Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute

James S. Huston, Ph.D., Chairman, The Antibody Society; Adjunct Scientist, Boston Biomedical Research Institute; Managing Member, Huston BioConsulting, LLC

James D. Marks M.D., Ph.D. Professor of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco

Andreas Plückthun, Ph.D., Professor of Biochemistry, Department of Biochemistry, University of Zürich, Switzerland

Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry, Simon Fraser University, Canada

Ian M. Tomlinson, Ph.D., Senior Vice President, Biopharmaceuticals R & D, GlaxoSmithKline, United Kingdom

Louis M. Weiner, M.D., Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

Antibody Therapeutics Scientific Advisory Board

Rathin C. Das, Ph.D., Chief Executive Officer, CEO, Synergys Biotherapeutics, Inc.

Mark R. Alfenito, Ph.D., President & CEO, EnGen Bio, Inc.

Benjamin P. Chen, Ph.D., International Director, Burrill & Company

Philip E. Thorpe, Ph.D., Serena S. Simmons Distinguished Chair in Cancer Immunopharmacology, University of Texas Southwestern Medical Center

Trudi Veldman, Ph.D., Director, Biologics Generation, Abbott Laboratories